The Quantra® System for Peripartum Obstetric Procedures

The HemoSonics OBI Campaign was launched to address a critical gap in obstetric care: the lack of real-time, actionable hemostasis data during postpartum hemorrhage (PPH). With PPH remaining a leading cause of maternal morbidity, clinicians often rely on delayed lab results, which can lead to guesswork and delayed intervention. The campaign announced a new indication for the Quantra® Hemostasis System, making it the first and only FDA 510(k) cleared viscoelastic testing system designed for obstetric use. Strategically tailored to three core audiences, obstetric clinicians, laboratorians, and hospital administrators, the campaign deployed a focused mix of in-market tactics: Google Search ads captured high-intent queries; display ads raised awareness among key stakeholders; organic LinkedIn content built credibility and conversation; and targeted email nurtures guided each audience through a phased journey from awareness to action. Messaging was meticulously customized: clinicians received data on rapid, bedside clotting assessments; laboratorians learned about streamlined workflows and compliance; administrators explored cost savings and improved maternal outcomes. Early performance demonstrated strong market engagement. Google Search achieved a 4.78% CTR, with Michigan emerging as a top-performing state. Display ads garnered over 146,000 impressions, with California showing notable engagement across all audience segments. These results reflect the campaign’s ability to connect urgent clinical needs with a transformative diagnostic solution. By aligning tailored messaging with measurable engagement, the HemoSonics OBI Campaign continues to promote the Quantra System and advanced the standard of care in obstetric hemorrhage management, turning uncertainty into clarity and action.